<DOC>
	<DOCNO>NCT02942706</DOCNO>
	<brief_summary>This study try evaluate effect cetuximab monotherapy maintenance treatment , versus continuation 8 course induction therapy cetuximab plus standard chemotherapy regimen ( FOLFIRI mFOLFOX6）in metastatic colorectal cancer ( mCRC ) patient . The maintenance treatment continue disease progression untolerated toxicity . The aim study demonstrate cetuximab monotherapy non-inferior continuation treatment , mCRC patient respond induction therapy ( SD , PR , CR ) , carry biomarker-panels ( KRAS , NRAS , BRAF , PIK3CA ) favor EGFR antibody .</brief_summary>
	<brief_title>Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy mCRC</brief_title>
	<detailed_description>This study try evaluate effect cetuximab monotherapy maintenance treatment , versus continuation 8 course induction therapy cetuximab plus standard chemotherapy regimen ( FOLFIRI mFOLFOX6）in metastatic colorectal cancer ( mCRC ) patient . The maintenance treatment continue disease progression untolerated toxicity . The aim study demonstrate cetuximab monotherapy non-inferior continuation treatment , mCRC patient respond induction therapy ( SD , PR , CR ) , carry biomarker-panels ( KRAS , NRAS , BRAF , PIK3CA ) favor EGFR antibody . Furthermore , mutation status biomarker panel consist KRAS , NRAS , HRAS , BRAF , EGFR , ERBB2 , ERBB3 , PIK3CA , PTEN , SMAD4 , SMAD2 , TGFBR2 , cMET , Src , mTOR , VEGFR1 , VEGFR2 , EPHA2 , MSI , TP53 , ERCC1 , ERCC5 , KCNQ5 , ILK , Myc analyze NGS sequence . The ctDNA surrogate marker via liquid biopsy conduct randomization , maintenance treatment , disease progression .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Before start induction therapy : Histological proof colorectal cancer ( case single metastasis , histological cytological proof lesion obtain ) ; Distant metastases either technically unresectable chance reach NED ( patient local recurrence eligible ) ; Measurable disease ( &gt; 1 cm spiral CT scan &gt; 2 cm chest Xray ; liver ultrasound allow ) . Serum CEA may use parameter disease evaluation ; Ongoing plan first line induction therapy 8 cycle FOLFIRI mFOLFOX6 . Exclusion criterion Prior adjuvant treatment stage II/III colorectal cancer end within 6 month start induction treatment Any prior adjuvant treatment resection distant metastases Previous systemic treatment advance disease RAS mutant mCRC At randomisation : Inclusion criterion : WHO performance status 01 ( Karnofsky PS &gt; 70 % ) ; Disease evaluation proven SD , PR CR accord RECIST 8 cycle FOLFIRI mFOLFOX6 ; Laboratory value obtain ≤ 2 week prior randomisation : adequate bone marrow function ( Hb &gt; 8.0 mmol/L , absolute neutrophil count &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L ) , renal function ( serum creatinine ≤ 1.5x ULN creatinine clearance , Cockroft formula , &gt; 30 ml/min ) , liver function ( serum bilirubin ≤ 2 x ULN , serum transaminase ≤ 3 x ULN without presence liver metastases ≤ 5x ULN presence liver metastasis ) ; Life expectancy &gt; 24 week ; Age : 1875 year ; Negative pregnancy test woman childbearing potential ; Expected adequacy followup ; Institutional Review Board approval ; Written inform consent Exclusion criterion Chronic active infection ; Any concurrent severe uncontrolled disease prevent safe administration study drug ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>